Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
(4) Adverse event costsExcluded because GLP-1 RA-related gastrointestinal symptoms are self-limited (medical intervention rate:1.2%3.5% [21]), and discontinuation rates were below significance thresholds in the SUSTAIN-7 trial [22]dulaglutide 2.4%, semaglutide 3.1%)
Hosokawa S, Hiasa Y, Miyazaki S, Ogura R, Miyajima H, Ohara Y, et al
Eligibility varies by specific trial but generally includes adults with BMI 27-30, often with obesity-related comorbidities
Product specifications, pricing, policies, availability, and program terms may change after publication without notice
By influencing hormones such as GLP-1, GIP, and glucagon, retatrutide not only curbs hunger but also enhances insulin sensitivity, making it a promising option for individuals struggling with obesity and type 2 diabetes
US$ 29.68
US$ 26.27
US$ 20.35
US$ 26.34
